Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant tetanus vaccine - Beijing Institute of Biotechnology/Sichuan ZehaTimes Pharmaceutical

Next Previous
X
Search
Drug Profile

Recombinant tetanus vaccine - Beijing Institute of Biotechnology/Sichuan ZehaTimes Pharmaceutical

Latest Information Update: 17 May 2018

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Institute of Biotechnology; Sichuan Zeha Times Pharmaceutical
  • Developer Sichuan Zeha Times Pharmaceutical
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Tetanus

Most Recent Events

  • 10 May 2018 Phase-I/II clinical trials in Tetanus (Prevention) in China (IM) (ChiCTR1800015865)
  • 25 Apr 2018 Sichuan ZehaTimes Pharmaceutical Co. Ltd. and Beijing Institute of Biotechnology plan a phase I/II trial for Tetanus (Prevention) in China, in May 2018 (ChiCTR1800015865),
  • 25 Apr 2018 Preclinical trials in Tetanus (Prevention) in China (IM), prior to April 2018

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top